<div class="welcome-screen" id="welcomeScreen">
    <div class="welcome-banner">
        <h1 id="welcome-title">Welcome to the page on Antiemetics and Antacids!</h1>
        <p id="welcome-description">Explore the following topics to enhance your knowledge.</p>
    </div>
    
    <div class="explanation-card">
        <h1>Introduction to Antiemetics and GERD Medications</h1>
        <h2>Anatomical and Physiological Foundations</h2>
        <p>The <b>emetic reflex</b> and <b>gastroesophageal reflux</b> share common anatomical pathways and neurochemical mediators, making their pharmacological management interrelated. The <b>vomiting center</b>, located in the medulla oblongata, receives inputs from:</p>
        <ol>
            <li>The <b>chemoreceptor trigger zone (CTZ)</b> in the area postrema (outside blood-brain barrier)</li>
            <li>The <b>vestibular system</b> (motion sickness)</li>
            <li>The <b>peripheral visceral afferents</b> from GI tract</li>
            <li>The <b>cerebral cortex</b> (psychogenic stimuli)</li>
        </ol>
        
        <p>The <b>lower esophageal sphincter (LES)</b>, a 3-4 cm segment of tonically contracted smooth muscle, serves as the primary barrier against GERD. Its pressure is influenced by:</p>
        <ol>
            <li><b>Hormonal factors</b> (cholecystokinin, progesterone decrease tone)</li>
            <li><b>Neural control</b> (vagal pathways via muscarinic receptors)</li>
            <li><b>Mechanical factors</b> (hiatal hernia disrupts function)</li>
        </ol>
        
        <h2>Historical Perspective</h2>
        <p>The development of antiemetics paralleled advances in neuropharmacology. <b>Phenothiazines</b> (e.g., chlorpromazine), initially developed as antipsychotics in the 1950s, were found to have potent antiemetic effects through dopamine receptor blockade. The discovery of <b>histamine H2-receptors</b> by James Black in 1972 revolutionized GERD treatment, leading to cimetidine's development.</p>
        
        <h2>Pathophysiological Mechanisms</h2>
        <p><b>Nausea and vomiting</b> involve multiple neurotransmitter systems:</p>
        <ol>
            <li><b>Dopamine (D2)</b>: CTZ stimulation</li>
            <li><b>Serotonin (5-HT3)</b>: Especially in chemotherapy-induced vomiting</li>
            <li><b>Muscarinic (M1)/Histamine (H1)</b>: Motion sickness pathway</li>
            <li><b>Substance P (NK1)</b>: Central emetic pathway</li>
        </ol>
        
        <p><b>GERD pathophysiology</b> involves:</p>
        <ol>
            <li><b>Transient LES relaxations (TLESRs)</b> (most common mechanism)</li>
            <li><b>Hypotensive LES</b> (<15 mmHg)</li>
            <li><b>Delayed gastric emptying</b></li>
            <li><b>Esophageal mucosal resistance</b> impairment</li>
        </ol>
    </div>

    <div class="question-card">
        <h1>Question 1</h1>
        <p>Which of the following structures is NOT part of the emetic pathway?</p>
        <ul class="options" id="options">
            <li data-answer="wrong">Chemoreceptor trigger zone</li>
            <li data-answer="wrong">Vestibular nuclei</li>
            <li data-answer="correct">Pineal gland</li>
            <li data-answer="wrong">Nucleus tractus solitarius</li>
        </ul>
    </div>

    <div class="question-card">
        <h1>Question 2</h1>
        <p>What is the primary mechanism of GERD in most patients?</p>
        <ul class="options" id="options">
            <li data-answer="wrong">Permanent LES hypotonia</li>
            <li data-answer="correct">Transient LES relaxations</li>
            <li data-answer="wrong">Increased gastric acid secretion</li>
            <li data-answer="wrong">Esophageal dysmotility</li>
        </ul>
    </div>

    <div class="explanation-card">
        <h1>Antiemetics: Pharmacological Agents</h1>
        <h2>5-HT3 Receptor Antagonists</h2>
        <p><b>Ondansetron, granisetron, palonosetron</b> are first-line for chemotherapy-induced nausea/vomiting (CINV). They block serotonin receptors in the CTZ and peripheral vagal afferents. <b>Palonosetron</b> has a 40-hour half-life and allosteric binding properties, making it superior for delayed CINV.</p>
        
        <div class="mnemonic">
            <b>MNEMONIC: "SEROTONIN Stops Sickness"</b><br>
            <b>S</b>elective 5-HT3 blockers<br>
            <b>E</b>xcellent for chemo<br>
            <b>R</b>adiation protection too<br>
            <b>O</b>ndansetron prototype<br>
            <b>T</b>orsades rare but possible<br>
            <b>O</b>ral/IV formulations<br>
            <b>N</b>o EPS side effects<br>
            <b>I</b>ntraoperative use<br>
            <b>N</b>o effect on motion sickness
        </div>
        
        <h2>NK1 Receptor Antagonists</h2>
        <p><b>Aprepitant, fosaprepitant, rolapitant</b> target substance P in the central pattern generator. Used in combination with 5-HT3 antagonists and dexamethasone for highly emetogenic chemotherapy (e.g., cisplatin). They are potent CYP3A4 inhibitors requiring dose adjustments of concomitant medications.</p>
        
        <h2>Dopamine Antagonists</h2>
        <p><b>Prochlorperazine, metoclopramide, droperidol</b> act at D2 receptors. Metoclopramide also has 5-HT4 agonist properties enhancing gastric emptying. High doses can cause <b>extrapyramidal symptoms</b> (acute dystonia, akathisia) via nigrostriatal pathway blockade.</p>
        
        <h2>Antihistamines/Anticholinergics</h2>
        <p><b>Diphenhydramine, meclizine, scopolamine</b> prevent motion sickness by blocking vestibular H1/M1 receptors. Scopolamine patches provide 72-hour coverage but can cause blurred vision and urinary retention.</p>
        
        <h2>Cannabinoids</h2>
        <p><b>Dronabinol, nabilone</b> act on CB1 receptors in the dorsal vagal complex. Used as refractory antiemetics but can cause euphoria, hypotension, and dependency.</p>
        
        <h2>Corticosteroids</h2>
        <p><b>Dexamethasone</b> is a cornerstone of antiemetic regimens, particularly for delayed CINV. Mechanism may involve prostaglandin inhibition and blood-brain barrier permeability reduction.</p>
    </div>

    <div class="question-card">
        <h1>Question 3</h1>
        <p>Which antiemetic class is MOST effective for motion sickness?</p>
        <ul class="options" id="options">
            <li data-answer="wrong">5-HT3 antagonists</li>
            <li data-answer="correct">Antihistamines</li>
            <li data-answer="wrong">Dopamine antagonists</li>
            <li data-answer="wrong">NK1 antagonists</li>
        </ul>
    </div>

    <div class="question-card">
        <h1>Question 4</h1>
        <p>A patient develops torticollis and oculogyric crisis after receiving an antiemetic. Which drug is MOST likely responsible?</p>
        <ul class="options" id="options">
            <li data-answer="wrong">Ondansetron</li>
            <li data-answer="correct">Metoclopramide</li>
            <li data-answer="wrong">Aprepitant</li>
            <li data-answer="wrong">Dexamethasone</li>
        </ul>
    </div>

    <div class="explanation-card">
        <h1>GERD Medications: Pharmacological Management</h1>
        <h2>Proton Pump Inhibitors (PPIs)</h2>
        <p><b>Omeprazole, esomeprazole, lansoprazole, pantoprazole, rabeprazole, dexlansoprazole</b> are irreversible inhibitors of H+/K+ ATPase. They require acidic activation and have <b>delayed onset</b> (2-3 days for full effect). Dexlansoprazole's dual-release formulation provides 24-hour coverage.</p>
        
        <div class="mnemonic">
            <b>MNEMONIC: "PUMP Inhibitors" for PPI characteristics</b><br>
            <b>P</b>arietal cell target<br>
            <b>U</b>lcer healing superior<br>
            <b>M</b>orning dosing best (before breakfast)<br>
            <b>P</b>rodrug activation in acidic space<br>
            <br>
            <b>Inhibit</b> H+/K+ ATPase<br>
            <b>N</b>ot instant (take 30-60 min pre-meal)<br>
            <b>D</b>yspepsia relief<br>
            <b>E</b>rosive esophagitis main use<br>
            <b>P</b>otent acid suppression<br>
            <b>Osteoporosis</b> risk with chronic use<br>
            <b>R</b>ebound hyperacidity on cessation
        </div>
        
        <h2>H2 Receptor Antagonists</h2>
        <p><b>Famotidine, ranitidine (withdrawn), cimetidine, nizatidine</b> competitively block histamine at parietal cell H2 receptors. Less potent than PPIs but faster onset (1 hour). <b>Cimetidine</b> inhibits CYP450 (warfarin, theophylline interactions).</p>
        
        <h2>Antacids/Alginates</h2>
        <p><b>Calcium carbonate, magnesium hydroxide, sodium alginate</b> provide immediate symptom relief by neutralizing acid and forming raft barriers. Magnesium salts cause diarrhea; aluminum causes constipation.</p>
        
        <h2>Potassium-Competitive Acid Blockers (P-CABs)</h2>
        <p><b>Vonoprazan</b> (available in some countries) reversibly blocks H+/K+ ATPase without requiring acid activation. Faster onset and less dependent on CYP2C19 polymorphism than PPIs.</p>
        
        <h2>Prokinetics</h2>
        <p><b>Metoclopramide, domperidone, erythromycin</b> enhance LES pressure and gastric emptying. Domperidone doesn't cross BBB (fewer EPS effects). Erythromycin acts as motilin agonist.</p>
        
        <h2>Baclofen</h2>
        <p>GABA-B agonist that reduces TLESRs. Limited by CNS side effects (drowsiness, dizziness).</p>
    </div>

    <div class="question-card">
        <h1>Question 5</h1>
        <p>Which GERD medication requires acidic activation for its mechanism of action?</p>
        <ul class="options" id="options">
            <li data-answer="correct">Omeprazole</li>
            <li data-answer="wrong">Famotidine</li>
            <li data-answer="wrong">Sodium alginate</li>
            <li data-answer="wrong">Baclofen</li>
        </ul>
    </div>

    <div class="question-card">
        <h1>Question 6</h1>
        <p>A patient on chronic PPI therapy should be monitored for which potential adverse effect?</p>
        <ul class="options" id="options">
            <li data-answer="wrong">QT prolongation</li>
            <li data-answer="correct">Hypomagnesemia</li>
            <li data-answer="wrong">Hyperkalemia</li>
            <li data-answer="wrong">Hypoglycemia</li>
        </ul>
    </div>

    <div class="explanation-card">
        <h1>Clinical Considerations and Special Populations</h1>
        <h2>Antiemetic Selection by Etiology</h2>
        <p>Tailoring antiemetics to the underlying cause improves efficacy:</p>
        <ol>
            <li><b>Chemotherapy-induced</b>: 5-HT3 antagonist + NK1 antagonist + dexamethasone</li>
            <li><b>Post-operative</b>: 5-HT3 antagonist ± droperidol</li>
            <li><b>Motion sickness</b>: Scopolamine patch ± antihistamine</li>
            <li><b>Pregnancy</b>: Pyridoxine (B6) + doxylamine (Category A)</li>
            <li><b>Gastroparesis</b>: Metoclopramide (limited duration due to EPS risk)</li>
        </ol>
        
        <h2>GERD Treatment Strategies</h2>
        <p>Step-up vs step-down approaches:</p>
        <ol>
            <li><b>Step-up</b>: Lifestyle modifications → antacids → H2RA → PPI</li>
            <li><b>Step-down</b>: Initial PPI → taper to lowest effective dose</li>
        </ol>
        <p><b>Refractory GERD</b> evaluation requires endoscopy, pH monitoring, and consideration of <b>PPI pharmacokinetics</b> (CYP2C19 polymorphisms affect metabolism).</p>
        
        <h2>Adverse Effects and Monitoring</h2>
        <p><b>PPIs</b>:</p>
        <ol>
            <li><b>Long-term risks</b>: Hypomagnesemia, B12 deficiency, osteoporosis, C. difficile infection</li>
            <li><b>Drug interactions</b>: Clopidogrel (omeprazole/esomeprazole inhibit CYP2C19 activation)</li>
        </ol>
        
        <p><b>Metoclopramide</b>: Black box warning for <b>tardive dyskinesia</b> (>12 weeks use).</p>
    </div>

    <div class="question-card">
        <h1>Question 7</h1>
        <p>Which antiemetic regimen is MOST appropriate for highly emetogenic chemotherapy?</p>
        <ul class="options" id="options">
            <li data-answer="wrong">Ondansetron alone</li>
            <li data-answer="correct">Ondansetron + aprepitant + dexamethasone</li>
            <li data-answer="wrong">Diphenhydramine + prochlorperazine</li>
            <li data-answer="wrong">Scopolamine patch</li>
        </ul>
    </div>

    <div class="question-card">
        <h1>Question 8</h1>
        <p>Which patient is at HIGHEST risk for PPI-induced hypomagnesemia?</p>
        <ul class="options" id="options">
            <li data-answer="wrong">18-year-old on short-course omeprazole</li>
            <li data-answer="correct">65-year-old on pantoprazole for 5 years with diuretics</li>
            <li data-answer="wrong">30-year-old pregnant woman on rabeprazole</li>
            <li data-answer="wrong">45-year-old on H2RA therapy</li>
        </ul>
    </div>

    <div class="placeholder" id="empty">Test</div>

</div>